Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

In vitro Cardiovascular Safety Pharmacology Models

Netzer R, Ebneth A, Bischoff U, Pongs O (2001) Screening lead compounds for QT interval prolongation. Drug Discovery Today 6(2) 78-84 [Pg.72]

Netzer R, Bischoff U, Ebneth A (2003) HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery. Current Opinion in Drug Discovery and Development 6(4) 462-469 Vandenberg JI, Walker BD, Campbell TC (2001) HERG K+channels friend and foe. Trends Pharmacol Sci 22 240-246 [Pg.72]

See other pages where In vitro Cardiovascular Safety Pharmacology Models is mentioned: [Pg.72]    [Pg.73]    [Pg.75]    [Pg.77]    [Pg.79]    [Pg.81]    [Pg.83]    [Pg.72]    [Pg.73]    [Pg.75]    [Pg.77]    [Pg.79]    [Pg.81]    [Pg.83]    [Pg.195]    [Pg.117]    [Pg.318]    [Pg.30]    [Pg.354]    [Pg.9]    [Pg.8]    [Pg.214]    [Pg.150]    [Pg.153]    [Pg.220]   


SEARCH



Cardiovascular Safety Pharmacology

Cardiovascular pharmacology

Cardiovascular safety

In vitro safety pharmacology

Safety in vitro

Safety models

Vitro Models

© 2024 chempedia.info